Cargando…

GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors

Cutaneous vascular tumors consist of a heterogeneous group of benign proliferations, including a range of hemangiomas and vascular malformations, as well as heterogeneous groups of both borderline and malignant neoplasms such as Kaposi’s sarcoma and angiosarcomas. The genetics of these tumors have b...

Descripción completa

Detalles Bibliográficos
Autores principales: Jansen, Philipp, Müller, Hansgeorg, Lodde, Georg C., Zaremba, Anne, Möller, Inga, Sucker, Antje, Paschen, Annette, Esser, Stefan, Schaller, Jörg, Gunzer, Matthias, Standl, Fabian, Bauer, Sebastian, Schadendorf, Dirk, Mentzel, Thomas, Hadaschik, Eva, Griewank, Klaus G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141909/
https://www.ncbi.nlm.nih.gov/pubmed/34040639
http://dx.doi.org/10.3389/fgene.2021.663272
_version_ 1783696466802376704
author Jansen, Philipp
Müller, Hansgeorg
Lodde, Georg C.
Zaremba, Anne
Möller, Inga
Sucker, Antje
Paschen, Annette
Esser, Stefan
Schaller, Jörg
Gunzer, Matthias
Standl, Fabian
Bauer, Sebastian
Schadendorf, Dirk
Mentzel, Thomas
Hadaschik, Eva
Griewank, Klaus G.
author_facet Jansen, Philipp
Müller, Hansgeorg
Lodde, Georg C.
Zaremba, Anne
Möller, Inga
Sucker, Antje
Paschen, Annette
Esser, Stefan
Schaller, Jörg
Gunzer, Matthias
Standl, Fabian
Bauer, Sebastian
Schadendorf, Dirk
Mentzel, Thomas
Hadaschik, Eva
Griewank, Klaus G.
author_sort Jansen, Philipp
collection PubMed
description Cutaneous vascular tumors consist of a heterogeneous group of benign proliferations, including a range of hemangiomas and vascular malformations, as well as heterogeneous groups of both borderline and malignant neoplasms such as Kaposi’s sarcoma and angiosarcomas. The genetics of these tumors have been assessed independently in smaller individual cohorts making comparisons difficult. In our study, we analyzed a representative cohort of benign vascular proliferations observed in a clinical routine setting as well as a selection of malignant vascular proliferations. Our cohort of 104 vascular proliferations including hemangiomas, malformations, angiosarcomas and Kaposi’s sarcoma were screened by targeted next-generation sequencing for activating genetic mutations known or assumed to be potentially relevant in vascular proliferations. An association analysis was performed for mutation status and clinico-pathological parameters. Frequent activating hotspot mutations in GNA genes, including GNA14 Q205, GNA11 and GNAQ Q209 were identified in 16 of 64 benign vascular tumors (25%). GNA gene mutations were particularly frequent (52%) in cherry (senile) hemangiomas (13 of 25). In angiosarcomas, activating RAS mutations (HRAS and NRAS) were identified in three samples (16%). No activating GNA or RAS gene mutations were identified in Kaposi’s sarcomas. Our study identifies GNA14 Q205, GNA11 and GNAQ Q209 mutations as being the most common and mutually exclusive mutations in benign hemangiomas. These mutations were not identified in malignant vascular tumors, which could be of potential diagnostic value in distinguishing these entities.
format Online
Article
Text
id pubmed-8141909
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81419092021-05-25 GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors Jansen, Philipp Müller, Hansgeorg Lodde, Georg C. Zaremba, Anne Möller, Inga Sucker, Antje Paschen, Annette Esser, Stefan Schaller, Jörg Gunzer, Matthias Standl, Fabian Bauer, Sebastian Schadendorf, Dirk Mentzel, Thomas Hadaschik, Eva Griewank, Klaus G. Front Genet Genetics Cutaneous vascular tumors consist of a heterogeneous group of benign proliferations, including a range of hemangiomas and vascular malformations, as well as heterogeneous groups of both borderline and malignant neoplasms such as Kaposi’s sarcoma and angiosarcomas. The genetics of these tumors have been assessed independently in smaller individual cohorts making comparisons difficult. In our study, we analyzed a representative cohort of benign vascular proliferations observed in a clinical routine setting as well as a selection of malignant vascular proliferations. Our cohort of 104 vascular proliferations including hemangiomas, malformations, angiosarcomas and Kaposi’s sarcoma were screened by targeted next-generation sequencing for activating genetic mutations known or assumed to be potentially relevant in vascular proliferations. An association analysis was performed for mutation status and clinico-pathological parameters. Frequent activating hotspot mutations in GNA genes, including GNA14 Q205, GNA11 and GNAQ Q209 were identified in 16 of 64 benign vascular tumors (25%). GNA gene mutations were particularly frequent (52%) in cherry (senile) hemangiomas (13 of 25). In angiosarcomas, activating RAS mutations (HRAS and NRAS) were identified in three samples (16%). No activating GNA or RAS gene mutations were identified in Kaposi’s sarcomas. Our study identifies GNA14 Q205, GNA11 and GNAQ Q209 mutations as being the most common and mutually exclusive mutations in benign hemangiomas. These mutations were not identified in malignant vascular tumors, which could be of potential diagnostic value in distinguishing these entities. Frontiers Media S.A. 2021-04-30 /pmc/articles/PMC8141909/ /pubmed/34040639 http://dx.doi.org/10.3389/fgene.2021.663272 Text en Copyright © 2021 Jansen, Müller, Lodde, Zaremba, Möller, Sucker, Paschen, Esser, Schaller, Gunzer, Standl, Bauer, Schadendorf, Mentzel, Hadaschik and Griewank. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Jansen, Philipp
Müller, Hansgeorg
Lodde, Georg C.
Zaremba, Anne
Möller, Inga
Sucker, Antje
Paschen, Annette
Esser, Stefan
Schaller, Jörg
Gunzer, Matthias
Standl, Fabian
Bauer, Sebastian
Schadendorf, Dirk
Mentzel, Thomas
Hadaschik, Eva
Griewank, Klaus G.
GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors
title GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors
title_full GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors
title_fullStr GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors
title_full_unstemmed GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors
title_short GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors
title_sort gna14, gna11, and gnaq mutations are frequent in benign but not malignant cutaneous vascular tumors
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141909/
https://www.ncbi.nlm.nih.gov/pubmed/34040639
http://dx.doi.org/10.3389/fgene.2021.663272
work_keys_str_mv AT jansenphilipp gna14gna11andgnaqmutationsarefrequentinbenignbutnotmalignantcutaneousvasculartumors
AT mullerhansgeorg gna14gna11andgnaqmutationsarefrequentinbenignbutnotmalignantcutaneousvasculartumors
AT loddegeorgc gna14gna11andgnaqmutationsarefrequentinbenignbutnotmalignantcutaneousvasculartumors
AT zarembaanne gna14gna11andgnaqmutationsarefrequentinbenignbutnotmalignantcutaneousvasculartumors
AT molleringa gna14gna11andgnaqmutationsarefrequentinbenignbutnotmalignantcutaneousvasculartumors
AT suckerantje gna14gna11andgnaqmutationsarefrequentinbenignbutnotmalignantcutaneousvasculartumors
AT paschenannette gna14gna11andgnaqmutationsarefrequentinbenignbutnotmalignantcutaneousvasculartumors
AT esserstefan gna14gna11andgnaqmutationsarefrequentinbenignbutnotmalignantcutaneousvasculartumors
AT schallerjorg gna14gna11andgnaqmutationsarefrequentinbenignbutnotmalignantcutaneousvasculartumors
AT gunzermatthias gna14gna11andgnaqmutationsarefrequentinbenignbutnotmalignantcutaneousvasculartumors
AT standlfabian gna14gna11andgnaqmutationsarefrequentinbenignbutnotmalignantcutaneousvasculartumors
AT bauersebastian gna14gna11andgnaqmutationsarefrequentinbenignbutnotmalignantcutaneousvasculartumors
AT schadendorfdirk gna14gna11andgnaqmutationsarefrequentinbenignbutnotmalignantcutaneousvasculartumors
AT mentzelthomas gna14gna11andgnaqmutationsarefrequentinbenignbutnotmalignantcutaneousvasculartumors
AT hadaschikeva gna14gna11andgnaqmutationsarefrequentinbenignbutnotmalignantcutaneousvasculartumors
AT griewankklausg gna14gna11andgnaqmutationsarefrequentinbenignbutnotmalignantcutaneousvasculartumors